BRIEF—Dimerix appoints chief medical officer

Melbourne’s Dimerix has appointed David Packham as chief medical officer. Mr Packham will head development of Dimerix’s lead therapeutic program, rare disease candidate DMX-200.

The firm is preparing a Phase II trial in focal segmental glomerulosclerosis (FSGS), a rare condition which causes nephrotic syndrome in children and adolescents, and is a leading cause of kidney failure in adults.

Mr Packham said: “The very positive DMX-200 Phase IIa clinical trial results in CKD announced last year provide a pathway for the development of next stage clinical studies in both the FSGS and diabetic nephropathy indications to test for efficacy.”